Compare Charles Schwab Corporation Common Stock (SCHW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? Charles Schwab Corporation Common Stock trades at $107.04 (market cap $186.75B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Charles Schwab Corporation Common Stock is the larger of the two by market cap, and Charles Schwab Corporation Common Stock pays a 1.19% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SCHW | VRTX | |
|---|---|---|
Market Cap | $186.75B | $132.79B |
Sector | Financials | Health |
52-Week High | $108.02 | $529.65 |
52-Week Low | $85.35 | $376.62 |
Dividend Yield | 1.19% | — |
Enterprise Value | — | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles Schwab (SCHW) trades at $107.60, down 0.06% on the day, near its all-time high of $109.05. The stock shows strong bullish momentum with earnings beats in recent quarters and a consensus analyst price target of $122.33. Revenue grew to $23.92 billion in 2025, with net income margin improving to 38.79%. Technical indicators signal bullish trends, though RSI levels suggest overbought conditions.
Outlook remains positive with robust earnings growth and institutional support, but risks include litigation exposure and competitive pressures. The stock offers upside potential aligned with analyst targets, contingent on sustained operational performance and market conditions.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
